Smad4-expression is decreased in breast cancer tissues: A retrospective study

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Stuelten, Christina H ^a,b,d   Buck, Miriam B ^b   Dippon, Juergen ^c   Roberts, Anita B ^d   Fritz, Peter ^a   Knabbe, Cornelius ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FORMALDEHYDE; PARAFFIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; SMAD4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; BREAST; BREAST TUMOR; CHEMISTRY; FEMALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETROSPECTIVE STUDIES; SMAD4 PROTEIN; SURVIVAL RATE;

EID: 33645221439     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-25     Document Type: Article

References (45)

1. Basolo F, Fiore L, Ciardiello F, Calvo S, Fontanini G, Conaldi PG, Toniolo A: Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int J Cancer 1994, 56:736-742.
2. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB: Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 1989, 141:353-361.
3. Dai JL, Bansal RK, Kern SE: G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc:4: phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci U S A 1999, 96:1427-32.
4. Derynck R: TGF-beta-receptor-mediated signaling. Trends Biochem Sci 1994, 19:548-53.
5. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth factor beta 1 asssociates with disease progression in human breast cancer. Cancer Res 1992, 52:6949-6952.
6. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET: Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 2001, 91:76-82.
7. Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003, 100:8621-8623.
8. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003, 100:8430-8435.
9. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K: Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. Embo J 1998, 17:4056-65.
10. Kloos DU, Choi C, Wingender E: The TGF-beta - Smad network: introducing bioinformatic tools. Trends Genet 2002, 18:96-103.
11. Heldin CH, Miyazono K, ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
12. Buck M, Fritz P, Dippon J, Zugmaier G, Knabbe C: Prognostic significance of Transforming Growth Factor beta receptor II in estrogen receptor negative breast cancer patients. Clin Cancer Res 2004, 10:1643-1657.
13. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-3.
14. Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH: Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000, 156:37-43.
15. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-6.
16. Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, Ishigami S, Baba M, Takao S, Aikou T: Smad4 and Transforming Growth Factor beta1 Expression in Patients with Squamous Cell Carcinoma of the Esophagus. Clin Cancer Res 2002, 8:1838-42.
17. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E, Kristo P, Jarvinen H, Souchelnytskyi S, Sarlomo-Rikala M, Aaltonen LA: Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002, 51:56-9.
18. Cardillo MR, Lazzereschi D, Gandini O, Di Silverio F, Colletta G: Transforming growth factor-beta pathway in human renal cell carcinoma and surrounding normal-appearing renal parenchyma. Anal Quant Cytol Histol 2001, 23:109-17.
19. Schutte M: DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Ann Oncol 1999, 10 Suppl 4:56-9.
20. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RAJ, Meltzer PS, Hahn SA, Kern SE: DPC4 gene in various tumor types. Cancer Res 1996, 56:2527-30.
21. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003, 112:1116-1124.
22. Remmele W, Stegner HE: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8:138-40.
23. Tian F, DaCosta BS, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, Roberts AB: Reduction in smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2003, 63:8284-8292.
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53:457-481.
25. Collett D: Modelling Survival Data in Medical Research 2nd edition. Chapman&Hall; 2003.
26. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR: Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001, 65:101-10.
27. Heppner GH, Miller FR, Shekhar PM: Nontransgenic models of breast cancer. Breast Cancer Res 2000, 2:331-4.
28. Soule HD, Maloney TM, Wolman SR, Peterson WDJ, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6075-86.
29. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijndenvan Raaij AJ: DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 1997, 14:1891-9.
30. Matsuda T, Yamamato T, Muraguchi A, Saatcioglu F: Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001, 276:42908-14.
31. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987, 48:417-28.
32. Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor beta by the anti-estrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 1991, 14 Suppl 2:S15-S20.
33. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M: Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002, 62:497-505.
34. Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW: Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol 2004, 17:756-764.
35. Xu J, Attisano L: Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 2000, 97:4820-4825.
36. Moren A, Hellman U, Inada Y, Imamura T, Heldin CH, Moustakas A: Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem 2003, 278:33571-33582.
37. Lee PS, Chang C, Liu D, Derynck R: Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem 2003, 278:27853-27863.
38. Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH: SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of turnor suppressor Smad4. J Biol Chem 2003, 278:31043-31048.
39. Pouliot F, Blais A, Labrie C: Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003, 63:277-281.
40. Pouliot F, Labrie C: Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 2002, 172:187-198.
41. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh CG: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 2000, 272:705-711.
42. Wakefield LM, Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12:22-9.
43. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005, 102:13909-13914.
44. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001, 10:917-923.
45. Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE, Roberts AB: Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2004, 64:4523-4530.